Carlsmed (NASDAQ:CARL) COO Jeffrey Bertolini Sells 747 Shares of Company Stock

Carlsmed, Inc. (NASDAQ:CARL) COO Jeffrey Bertolini sold 747 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $15.15, for a total value of $11,317.05. Following the sale, the chief operating officer directly owned 22,489 shares in the company, valued at approximately $340,708.35. The trade was a 3.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jeffrey Bertolini also recently made the following trade(s):

• On Friday, October 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The shares were sold at an average price of $15.80, for a total value of $3,839.40.
• On Monday, October 5th, Jeffrey Bertolini sold 747 shares of Carlsmed stock. The stock was sold at an average price of $14.39, for a total transaction of $10,749.33.
• On Wednesday, September 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The shares were sold at an average price of $13.99, for a total transaction of $3,399.57.

Carlsmed Stock Up 12.2%

Shares of CARL stock traded up $1.75 during mid-day trading on Wednesday, hitting $16.15. 90,824 shares of the stock traded hands, compared to its average volume of 132,142. Carlsmed, Inc. has a 52-week low of $8.50 and a 52-week high of $17.23. The stock has a market cap of $440.89 million, a P/E ratio of -11.29 and a beta of 1.97. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66. The stock’s fifty day moving average is $14.98 and its two-hundred day moving average is $12.46.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The firm had revenue of $18.94 million for the quarter. Equities analysts predict that Carlsmed, Inc. will post -1.50 EPS for the current year.

Analysts Set New Price Targets

CARL has been the subject of several recent analyst reports. Truist Financial raised their target price on shares of Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings raised Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, BTIG Research raised their price objective on Carlsmed from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Carlsmed currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

Hedge Funds Weigh In On Carlsmed

Several hedge funds have recently modified their holdings of CARL. Deutsche Bank AG acquired a new stake in Carlsmed in the 2nd quarter worth approximately $106,000. Bank of America Corp DE purchased a new stake in Carlsmed during the 2nd quarter worth approximately $108,000. Alpine Woods Capital Investors LLC purchased a new stake in Carlsmed during the 2nd quarter worth approximately $161,000. Bank of New York Mellon Corp acquired a new position in Carlsmed during the 2nd quarter valued at approximately $181,000. Finally, Zevenbergen Capital Investments LLC increased its stake in Carlsmed by 50.4% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after purchasing an additional 6,000 shares in the last quarter.

Carlsmed Company Profile

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients.

Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.

Carlsmed serves the spine-care market through relationships with spine surgeons, hospitals and other healthcare providers.